The American Journal of Managed Care5h
FDA Approves Optune Lua Device in NSCLC
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
Medscape5h
The Long Shots: When Patients Defy All Odds
Oncologists never know which patients with dire prognoses will be among the rare, but real responders. The few who defy all ...
FierceBiotech6h
Novocure nets FDA approval for Tumor Treating Fields in metastatic lung cancer
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
Targeted Oncology6h
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
Jazz Pharmaceuticals’ Zepzelca combination meets endpoints in lung cancer trial
Jazz Pharmaceuticals announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca in combination ...
Yahoo Finance9h
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel ...
The Pharma Letter10h
FDA approves Novocure’s Optune Lua
The US Food and Drug Administration (FDA) has approved Novocure's Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or ...
The Lancet11h
Embracing more treatment choices for metastatic, recurrent, or persistent cervical cancer
Notably, 370 (83%) participants had squamous cell carcinoma, 215 (48%) had received previous chemoradiotherapy, 116 (26%) had a programmed cell death ligand 1 (PD-L1) combined positive score (CPS) of ...
Buy Rating Affirmed for NovoCure as FDA Approval Expands Optune’s Market Potential
Larry Biegelsen, an analyst from Wells Fargo, maintained the Buy rating on NovoCure (NVCR – Research Report). The associated price target ...
bovnews20h
Novocure’s (NVCR) Optune Lua Approval Sparks Market Surge
In a significant development for cancer treatment, Novocure (NASDAQ: NVCR) announced that the U.S. Food and Drug Administration (FDA) has approved its innovative device, Optune Lua®, for use in ...
Business Wire22h
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...
Novocure Shares Rise After FDA Approves Optune Lua Cancer Treatment
Shares of Novocure were trading higher in Tuesday's late session after the company said that the Food and Drug Administration had approved Optune Lua, its wearable treatment for certain types of lung ...